Deutsche Bank Sets $86 Price Target as FDA Clears DexCom Pediatric CGM
DXCM•Deutsche Bank initiated coverage on DexCom with a Buy rating and set a price target of $86, implying a potential 24.5% upside. The FDA has expanded DexCom’s Stelo Glucose Biosensor System for over-the-counter pediatric use down to age two, broadening its addressable market for continuous glucose monitoring.
1. Deutsche Bank Initiates Coverage
Deutsche Bank has started research coverage on DexCom, assigning a Buy rating and an $86 price target, representing 24.5% upside potential.
2. FDA Expands Pediatric Clearance
The FDA has approved over-the-counter use of DexCom’s Stelo Glucose Biosensor System for children aged two and older, marking the first CGM cleared for pediatric OTC application.
3. Stelo System Features
Built on the G7 platform, Stelo delivers glucose readings to smartphones every 15 minutes with sensors worn up to 15 days, enhancing convenience and real-time diabetes management.
4. Implications of Price Target
Analyst confidence reflected in the $86 price target underscores expectations for revenue growth from expanded pediatric and adult CGM markets, potentially accelerating market share gains.
